Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Bellevue Hospital Center, AIDS Clinical Trials Unit, New York University School of Medicine, 550 First Avenue, BCD 5 (Room 558), NY 10016, USA. judith.aberg@nyumc.org
Dyslipidemia now is recognized as a significant potential adverse event in HIV-infected patients who are receiving antiretroviral therapy. HIV-infected persons who have hyperlipidemia should be managed similarly to those without HIV infection in accordance with the National Cholesterol Education Program. Providers must treat the HIV infection first; if dyslipidemia develops, patients should be prescribed lipid-lowering therapies or should consider modifying their current antiretroviral therapy, if indicated. Evidence for these two strategies is discussed.
Images from this publication.See all images (1) Free text
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on